New hope for esophageal cancer patients: adding immunotherapy before standard treatment
NCT ID NCT07306663
Summary
This study is testing whether adding an immunotherapy drug called sintilimab to standard chemotherapy before radiation treatment helps people with inoperable esophageal cancer live longer and keeps the cancer from coming back. Researchers will compare this new combination approach against the current standard treatment of chemotherapy and radiation together. The trial will also carefully track any side effects participants experience during treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, 210009, China
Conditions
Explore the condition pages connected to this study.